BION Share Price Performance
CHF 49.55
16.50 (49.92%)
23.8% undervalued intrinsic discount
CHF 65.00
Fair Value
Price CHF 49.55
AnalystLowTarget CHF 65.00
AnalystConsensusTarget CHF 69.00
Fair ValueCHF 65.00
Share Pricen/a
Narrative Update • Jun 26
BB Biotech AG Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
BION Community Narratives
AN
Fair Value
·Fair Value CHF 65 23.8% undervalued intrinsic discount
Patent Cliff Demand And Rate Volatility Will Pressure Biotech Portfolio Fundamentals
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value CHF 69 28.2% undervalued intrinsic discount
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Patent Cliff Demand And Rate Volatility Will Pressure Biotech Portfolio Fundamentals
BB Biotech leans on late-stage drug makers at a time when big pharma needs new medicines to replace aging blockbusters, but deal prices and financing conditions could make those wins harder to capture. See why a more cautious view argues that even with ongoing takeover interest, portfolio results could be squeezed if buyers pull back or borrowing costs stay jumpy.Read more
AN
CHF 65
23.8% undervalued intrinsic discount
Fair Value
Revenue
30.73% p.a.
Profit Margin
22.82%
Future PE
13.21x
Price in 2029
CHF 73.2
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
Catalysts About BB Biotech BB Biotech invests in a concentrated portfolio of biotech companies with a focus on late stage clinical and early commercial assets. What are the underlying business or industry changes driving this perspective?Read more
AN
CHF 69
28.2% undervalued intrinsic discount
Fair Value
Revenue
27.61% p.a.
Profit Margin
23.66%
Future PE
14.77x
Price in 2029
CHF 79.05
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
None
Fair Value: CHF 65 23.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Biotech Focus And M&A Tailwinds Will Support Long Term Portfolio Outcomes
Fair Value: CHF 69 28.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BB Biotech AG Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 24, 2026
- 14.46
- 100.00%
- 129.31%
- 0%
About BION
- Founded
- 1993
- Employees
- 10
- CEO
- WebsiteView website
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
